Kantonsspital Olten

Running trials

• Recruiting

  Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT07149649· Phase 2/3· Source

• Not yet recruiting

  Anakinra for the Treatment of Postprandial Hypoglycemia in a Patient With Total Gastrectomy and End-Stage Renal Disease

  NCT07580079· Phase 2· Source

• Active, not recruiting

  Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

  NCT07220759· Phase 3· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Source

• Enrolling by invitation

  A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

  NCT07055607· Source

• Recruiting

  GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

  NCT06630585· Phase 3· Source

• Recruiting

  Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia

  NCT06047262· Phase 2· Source

• Active, not recruiting

  Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

  NCT04472949· Phase 2· Source

• Active, not recruiting

  Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

  NCT04604067· Phase 2· Source

• Active, not recruiting

  Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT04822181· Phase 3· Source

• Active, not recruiting

  SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

  NCT04775082· Phase 3· Source

• Active, not recruiting

  Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

  NCT04608318· Phase 3· Source

• Recruiting

  The SwissPrEPared Study

  NCT03893188· Source

• Active, not recruiting

  Prostate Cancer Biobank

  NCT04024475· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• HIV1 recruiting
• Lung cancer1 recruiting
• Obesity1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

  NCT07357766· Phase 3· Source

• Completed

  Emp-Activity: Empagliflozin Functional Capacity

  NCT05350202· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

  NCT05259033· Phase 3· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· Source

• Terminated

  Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

  NCT02051218· Phase 3· Source

• Terminated

  SwissNET - a Registry for Neuroendocrine Tumours in Switzerland

  NCT01039922· Source

• Completed

  Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) Study

  NCT00470587· Source